H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on CalciMedica (CALC) to $16 from $20 and keeps a Buy rating on the shares. The firm believes the Phase 2b CARPO data “represent a significant step forward” in the clinical advancement of Auxora. It cites dilution from the equity raise for the target cut.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALC: